# A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

> **NCT03367689** · PHASE2 · TERMINATED · sponsor: **MedSIR** · enrollment: 7 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03367689
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-17
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Very slow recruitment due to subject profile
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367689, "A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03367689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*